Clinical Trials in Padova, Padova
10 recruiting
Showing 1–10 of 10 trials
Recruiting
Treosulfan Therapeutic Drug Monitoring in Pediatric Hematopoietic Stem Cell Transplant Recipients
Non-malignant DisordersPediatric Hematopoietic Stem Cell TransplantationMalignant Disorders
Fondazione IRCCS Policlinico San Matteo di Pavia70 enrolled10 locationsNCT06861257
Recruiting
Assessment of Sexual Well-being in Patients With Gynecologic Cancer and Their Partners: the ONCOSEX Study
Gynecologic CancersSexual Wellness
Casa di Cura Dott. Pederzoli200 enrolled6 locationsNCT07557342
Recruiting
Phase 3
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
Brain TumorGlioblastomaGBM+1 more
Ivy Brain Tumor Center450 enrolled95 locationsNCT06388733
Recruiting
The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)
Sarcoma,Soft TissueEpithelioid Hemangioendothelioma
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano100 enrolled22 locationsNCT06408441
Recruiting
Reference Intervals With Indirect Methods in Italy
Reference Intervals
Centro di Riferimento Oncologico - Aviano1,000,000 enrolled24 locationsNCT07433777
Recruiting
Not Applicable
Training App for Inhibitory Control Towards Food
Bulimia NervosaBinge-Eating DisorderObesity &Amp; Overweight
University of Padova113 enrolled1 locationNCT07075952
Recruiting
Not Applicable
Interventions to Promote Well-being and Social Relationships Among University Students
LonelinessPsychological Well-beingSocial Relationship
University of Padova50 enrolled1 locationNCT07147712
Recruiting
A Master Protocol Empowering Mechanobiology Translation Research in Breast Cancer
Breast Cancer
IFOM ETS - The AIRC Institute of Molecular Oncology1,500 enrolled10 locationsNCT04625023
Recruiting
Phase 2
NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast Cancer
Breast Cancer
Fondazione Oncotech51 enrolled8 locationsNCT06259929
Recruiting
Study to Assess Effectiveness and Safety of Zanubrutinib for Patients With Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)
Marginal Zone Lymphoma (MZL)
IRCCS Azienda Ospedaliero-Universitaria di Bologna59 enrolled15 locationsNCT06823960